Oncternal Therapeutics Q2 EPS $(0.15) Beats $(0.16) Estimate, Sales $106.00K Miss $200.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Oncternal Therapeutics reported Q2 EPS of $(0.15), beating the estimate of $(0.16) by 6.25%. However, the company's sales of $106.00K missed the estimate of $200.00K by 47%. This represents a 34.78% increase in EPS and a 44.5% decrease in sales compared to the same period last year.
August 10, 2023 | 8:41 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oncternal Therapeutics' Q2 EPS beat estimates, but sales missed, indicating mixed financial performance.
Oncternal Therapeutics reported a better than expected EPS, which is a positive signal for investors. However, the company's sales missed estimates, which could be a concern. The mixed results may lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100